Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Blumberg Website

Peter M. Blumberg, Ph.D.

Selected Publications

1)  Chen J, R Heldman M, Herrmann MA, Kedei N, Woo W, Blumberg PM, Goldsmith PK.
Absolute quantitation of endogenous proteins with precision and accuracy using a capillary western system.
Anal. Biochem. in press, 2013.
In Press. [Journal]
2)  Song X, Lopez-Campistrous A, Sung L, Dower N, Kedei N, Yang J, Kelsey J, Lewin N, Esch T, Blumberg P, Stone J.
RasGRPs are targets of the anti-cancer agent ingenol 3-angelate.
PLOS One. in press, 2013.
In Press. [Journal]
3)  Thorat SA, Kang DW, Ryu H, Kim MS, Kim HS, Ann J, Ha T, Kim SE, Son K, Choi S, Blumberg PM, Frank R, Bahrenberg G, Schiene K, Christoph T, Lee J.
2-(3-Fluoro-4-methylsulfonylaminophenyl)propanamides as potent TRPV1 antagonists: structure activity relationships of the 2-oxy pyridine C-region.
Eur J Med Chem. 64: 589-602, 2013.
[Journal]
4)  Kortum RL, Rouquette-Jazdanian AK, Miyaji M, Merrill RK, Markegard E, Pinski JM, Wesselink A, Nath NN, Alexander CP, Li W, Kedei N, Roose JP, Blumberg PM, Samelson LE, Sommers CL.
A phospholipase C-?1-independent, RasGRP1-ERK-dependent pathway drives lymphoproliferative disease in linker for activation of T cells-Y136F mutant mice.
J. Immunol. 190: 147-58, 2013.
[Journal]
5)  Kedei N, Lewin NE, Géczy T, Selezneva J, Braun DC, Chen J, Herrmann MA, Heldman MR, Lim L, Mannan P, Garfield SH, Poudel YB, Cummins TJ, Rudra A, Blumberg PM, Keck GE.
Biological Profile of the Less Lipophilic and Synthetically More Accessible Bryostatin 7 Closely Resembles That of Bryostatin 1.
ACS Chem. Biol. 8(4): 767-777, 2013.
[Journal]
6)  Kedei N, Telek A, Michalowski AM, Kraft MB, Li W, Poudel YB, Rudra A, Petersen ME, Keck GE, Blumberg PM.
Comparison of transcriptional response to phorbol ester, bryostatin 1, and bryostatin analogs in LNCaP and U937 cancer cell lines provides insight into their differential mechanism of action.
Biochem. Pharmacol. 85: 313-24, 2013.
[Journal]
7)  Rahman GM, Shanker S, Lewin NE, Kedei N, Hill CS, Prasad BV, Blumberg PM, Das J.
Identification of the activator-binding residues in the second cysteine-rich regulatory domain of protein kinase C? (PKC?).
Biochem. J. 451: 33-44, 2013.
[Journal]
8)  van Veghel D, Cleynhens J, Pearce LV, Deandrea-Lazarus IA, Blumberg PM, Van Laere K, Verbruggen A, Bormans G.
New Transient Receptor Potential Vanilloid Subfamily Member 1 Positron Emission Tomography Radioligands: Synthesis, Radiolabeling, and Preclinical Evaluation.
ACS Chem Neurosci. 4(4): 624-634, 2013.
[Journal]
9)  van Veghel D, Cleynhens J, Pearce LV, Blumberg PM, Van Laere K, Verbruggen A, Bormans G.
Synthesis and biological evaluation of [11C]SB366791: a new PET-radioligand for in vivo imaging of the TRPV1 receptor.
Nucl. Med. Biol. 40: 141-7, 2013.
[Journal]
10)  Kim MS, Ryu H, Kang DW, Cho SH, Seo S, Park YS, Kim MY, Kwak EJ, Kim YS, Bhondwe RS, Kim HS, Park SG, Son K, Choi S, DeAndrea-Lazarus IA, Pearce LV, Blumberg PM, Frank R, Bahrenberg G, Stockhausen H, Kögel BY, Schiene K, Christoph T, Lee J.
2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides as potent transient receptor potential vanilloid 1 (TRPV1) antagonists: structure-activity relationships of 2-amino derivatives in the N-(6-trifluoromethylpyridin-3-ylmethyl) C-region.
J. Med. Chem. 55: 8392-408, 2012.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 8/20/2013.